MedTrace Logo

Efficacy of Fructose Metabolizing Enzymatic Product in Fructose Malabsorption

NCT00916487 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 65

Last updated 2010-12-20

No results posted yet for this study

Summary

The purpose of this study is to determine whether the enzymatic product Frucosin(R) is able to degrade fructose in vivo in the small intestine of patients with known fructose malabsorption by measuring hydrogen in the expiratory air.

Conditions

  • Fructose Malabsorption

Interventions

DIETARY_SUPPLEMENT

Fructosin

Three capsules of Fructosin before one of the hydrogen breath tests.

Sponsors & Collaborators

  • Austrian Research Promotion Agency

    collaborator OTHER_GOV

  • Sciotec Diagnostic Technologies GmbH

    lead INDUSTRY

Principal Investigators

  • Peter Komericki, MD · Medical University of Graz

  • Christian Pongracz, MS · Sciotec Diagnostic Technologies GmbH

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
CROSSOVER

Eligibility

Min Age
18 Years
Max Age
80 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2009-06-30
Primary Completion
2010-05-31
Completion
2010-08-31

Countries

  • Austria

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00916487 on ClinicalTrials.gov